Table 1 Subject characteristics^a

Prior vaccination	Pfizer	Moderna	AstraZeneca	Janssen	Total
No. of subjects	55	2	4	10	71
Duration from Last Vax dose to AKS-452 dose (days; mean ± SEM)	279 ± 7	308, 321	354 ± 13	324 ± 10	291 ± 12
Sex [N (%)]
Male	20 (36%)	1 (50%)	2 (50%)	4 (40%)	27 (38%)
Female	35 (64%)	1 (50%)	2 (50%)	6 (60%)	44 (62%)
Age (years)
Median[range]	29.5	N/A	53	26.9	30.7
Median[range]	[18–57]	[26, 50]	[24–64]	[19–47]	[18–64]
Race/Ethnicity - N (%)
Caucasian	53 (96%)	2 (100%)	4 (100%)	10 (100%)	69 (97%)
Other	2 (4%)	0	0	0	2 (3%)
Body Mass Index
Median[range]	23.5	N/A	22.7	24.2	23.8
Median[range]	[19.1–33.1]	[26.5, 29.2]	[19.8–29.9]	[20.1–26.4]	[19.1–33.13]
Allergies - N (%)
Allergy^b	7 (foods, meds, animals, pollen)	0	1 (food/animals)	1 (food)	9 (12.7%)
Symptomatic COVID-19 prior to enrollment^c
N (%)	46 (84%)	0	4 (100%)	9 (90%)	59 (83%)

^aNone of the 71 subjects enrolled had diabetes, cardiovascular, pulmonary, hematologic, rheumatologic, endocrine, autoimmune, or renal diseases, or chronic viral or bacterial infection.
^bAllergies to foods (nuts/peanut, oranges, pineapple), medications (nitrofurantoin, amoxicillin), grasses/pollen, and/or animals (cat, dog, dust mite); note that no subject was actively on allergy medication during the trial.
^cThe duration between end of symptoms and the AKS-452 dose was 290.7 ± 12.5 (mean ± SEM, days); median day (range, days), 299.5 (113.5–399.4)

Quick links

Search